洛匹那韦利托那韦片致1例不良反应及文献分析

doi:10.19803/j.1672-8629.2020.07.04

中国药物警戒 ›› 2020, Vol. 17 ›› Issue (7): 399-402.
DOI: 10.19803/j.1672-8629.2020.07.04

• 新型冠状病毒肺炎诊疗药品安全研究专栏 • 上一篇下一篇

洛匹那韦利托那韦片致1例不良反应及文献分析

安薇, 田莹^*, 陈敏, 杨萍, 张明伟

湖北省第三人民医院药学部,湖北武汉 430033

收稿日期:2020-03-17 修回日期:2020-06-22 出版日期:2020-07-15 发布日期:2020-06-22
通讯作者: ^*田莹,女,本科,主管药师,医院药学。E-mail:1454164565@qq.com
作者简介:安薇,女,硕士,副主任药师,医院药学、临床药学。
基金资助:
湖北省卫生健康委员会指导性项目（WJ2019F170）：湖北省基层医院药事管理现状与对策研究

A Case of Adverse Drug Reactions of Lopinavir and Ritonavir Tablets and Literature Analysis

AN Wei, TIAN Ying^*, CHEN Min, YANG Ping, ZHANG Mingwei

Department of Pharmacy, the Third People's Hospital of Hubei Province, Wuhan Hubei 430033, China

Received:2020-03-17 Revised:2020-06-22 Online:2020-07-15 Published:2020-06-22

摘要/Abstract

摘要： 目的分析洛匹那韦利托那韦片致新型冠状病毒肺炎患者不良反应1例,为临床用药提供参考依据。方法收集湖北省第三人民医院临床确诊的1例新型冠状病毒肺炎患者的临床资料,包括病史情况、体格检查、诊疗方案、实验室及影像学检查,探讨患者治疗期间发生恶心呕吐、腹泻及鼻出血与用药的关联性。结果通过对患者治疗经过和出现不良反应后的处理过程的分析,依据国家《药品不良反应报告和监测管理办法》中的因果关系评价方法,对洛匹那韦利托那韦致恶心呕吐、腹泻及鼻出血进行相关性评价,考虑以上症状很可能为抗病毒药物洛匹那韦利托那韦片导致的药品不良反应。结论新型冠状病毒肺炎的抗病毒治疗推荐试用洛匹那韦利托那韦,但要注意该药相关恶心呕吐、腹泻等不良反应,同时要注意和其他药物的相互作用。

关键词: 洛匹那韦利托那韦, 新型冠状病毒肺炎, 药品不良反应

Abstract: Objective To analyze the adverse reactions of lopinavir and ritonavir tablets in a COVID-19 patient in order to provide reference for clinical medication. Methods The clinical data of a patient with newly diagnosed COVID -19 in the Third People's Hospital of Hubei province was collected, including medical history, results of physical examination, diagnosis and treatment plans, outcomes of laboratory and imaging examination. The relationships between nausea, vomiting, diarrhea, epistaxis and medication were determined. Results Based on the analysis of the patient's medication and treatment of adverse reactions, and according to the national Provisions for Adverse Drug Reaction Reporting and Monitoring, the correlations of lopinavir and ritonavir with nausea, vomiting, diarrhea and epistaxis were evaluated. It was found that the above symptoms were probably caused by the antiviral drug lopinavir and ritonavir. Conclusion Lopinavir and ritonavir is recommended for the antiviral treatment of COVID -19, but it is worth noting that it is associated with such adverse reactions as nausea, vomiting, diarrhea and interactions with other drugs.

Key words: lopinavir and ritonavir, COVID -19, adverse drug reaction

中图分类号:

R994.1

安薇, 田莹, 陈敏, 杨萍, 张明伟. 洛匹那韦利托那韦片致1例不良反应及文献分析[J]. 中国药物警戒, 2020, 17(7): 399-402.

AN Wei, TIAN Ying, CHEN Min, YANG Ping, ZHANG Mingwei. A Case of Adverse Drug Reactions of Lopinavir and Ritonavir Tablets and Literature Analysis[J]. Chinese Journal of Pharmacovigilance, 2020, 17(7): 399-402.

参考文献

[1] Hui DS, Azhar EI, Madani TA, et al.The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan,China[J]. International Journal of Infectious Disease, 2020,91: 264-266.
[2] Tan WJ, Zhao X, Ma XJ, et al.A novel coronavirus genome ident-ified in a cluster of pneumonia cases-Wuhan China 2019 - 2020[J].China CDC Weekly, 2020, 2(4): 61-62.
[3] Cui J, Li F, Shi Z.Origin and evolution of pathogenic coronaviruses[J].Nature Reviews Microbiology,2019, 17(3): 181-192.
[4] 中华人民共和国国家卫生健康委员会.新型冠状病毒肺炎诊疗方案(试行第六版)[EB/OL].(2020-02-19)[2020-02-19].http://www.nhc.gov.cn/wjw/index.shtml.
[5] 陈利娟,任丽娟. 我中心2011-2014年抗艾滋病毒药物应用分析[J]. 中国药房, 2017, 28(17): 2336-2339.
[6] Bates DE, Herman RJ.Carbamazepine toxicity induced by lopinavir /ritonavir and nelfinavi[J]. The Annals of pharmacotherapy,2006, 40(6): 1190-1195.
[7] Borrs-Blasco J, Bda A, Rosique-Robles D, et al.Hairloss induced by lopinavir /ritonavir[J]. Pharmacotherapy, 2007, 27(8):1215-1218.
[8] Kim HS, Shin HS.Alopecia areata associated with abacavir therapy[J]. Infect Chemother, 2014, 46(2):103-105.
[9] Greffrath WP, Plessis JM, Viljoen M, et al.Hypertriglyceridaemia and the risk of pancreatitis six months post lopinavir/ritonavirinitiation[J]. South Afr J HIV Med, 2018, 19(1): 766.
[10] Bandeira ACPCS, Elias DBD, Cavalcante MG.Antiretroviral changes during the first year of therapy[J]. Rev Assoc Med Bras,2017, 63(7):606-612.
[11] Sunita G, Alecia GK, Boriss YL, et al.Brain Injury Caused by HIV Protease Inhibitors: role of Lipodystrophy and Insulin Resistance[J].Antiviral Res, 2012, 95(1):19-29.
[12] Chu CM, Cheng VCC, Hung IFN, et al.Role of lopinavir /ritonavir in the treatment of SARS:initial virological and clinical findings[J]. Thorax, 2004, 59(3): 252-256.
[13] Chen N, Zhou M, Dong X, et al.Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan,China: a descriptive study[J]. The Lancet, 2020,395(10223): 507-513.
[14] 江华,邓洪飞,王宇,等. 洛匹那韦利托那韦(LPV/r)用于2019新型冠状病毒肺炎的治疗可能性:基于既往冠状病毒肺炎研究的快速系统评价[J]. 中华急诊医学杂志, 2020, 29(2):182-185.
[15] 靳英辉,蔡林,程真顺,等. 新型冠状病毒(2019-nCoV)感染的肺炎诊疗快速建议指南(标准版)[J]. 解放军医学杂志,2020, 45(1): 1-20.

洛匹那韦利托那韦片致1例不良反应及文献分析

A Case of Adverse Drug Reactions of Lopinavir and Ritonavir Tablets and Literature Analysis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	贾晋生, 刘红亮, 王青, 侯永芳, 李馨龄. 基于知识图谱联合ERNIE-DPCNN模型的药品不良反应自动关联性评价方法研究[J]. 中国药物警戒, 2024, 21(2): 163-166.
[2]	李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198.
[3]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[4]	郭清华, 彭笑笑, 朱萍, 刘西霖, 杨颖华, 陈志海. 氨氯地平过量致多器官功能障碍综合征1例分析[J]. 中国药物警戒, 2024, 21(2): 204-207.
[5]	方美琳, 郑慧敏, 王存泽, 王凌, 阮君山. 注射用奥沙利铂致全身肌肉疼痛1例分析[J]. 中国药物警戒, 2024, 21(2): 208-210.
[6]	陈玉艳, 张明霞, 张涛, 张晋. 斯鲁利单抗注射液致间质性肺炎不良反应1例分析[J]. 中国药物警戒, 2024, 21(2): 213-215.
[7]	曹桂萍, 邓琳琳, 朱干红, 陆颖, 马爽, 陈玲玲, 刘丽丽. 天麻首乌片致严重肝损伤1例分析[J]. 中国药物警戒, 2024, 21(2): 216-218.
[8]	高云娟, 赵旭, 白天凯, 柏兆方, 王伽伯, 宋海波, 肖小河. 基于不良反应监测大数据的药品安全风险发现与识别策略[J]. 中国药物警戒, 2024, 21(1): 1-5.
[9]	郭龙鑫, 高云娟, 吴承钊, 龙敏娟, 祝胜凯, 宋海波, 赵旭, 肖小河. 基于不良反应监测大数据的中药药源性肝损伤风险信号新发现及易感因素初探[J]. 中国药物警戒, 2024, 21(1): 15-19.
[10]	蒋文硕, 杨莉. 694例癫痫医师药师联合门诊患者药品不良反应分析[J]. 中国药物警戒, 2024, 21(1): 102-106.
[11]	陈华炎, 江东波, 郭春连, 杨家琪, 黎雨欣, 蔡伟明. 326例奈玛特韦片/利托那韦片治疗新型冠状病毒感染安全性分析[J]. 中国药物警戒, 2024, 21(1): 107-110.
[12]	刘赛月, 吕小琴, 周耘. 疑似药品不良反应死亡病例调查及报告实施要点[J]. 中国药物警戒, 2023, 20(9): 971-974.
[13]	里筱竹, 王蔷, 逄瑜, 张轶菁. 个例药品不良反应报告管理浅析与思考[J]. 中国药物警戒, 2023, 20(9): 975-977.
[14]	逄瑜, 刘博, 吕少俐, 王涛, 邢颖, 秦星宇, 田月洁, 吴文宇. 基于国际药物警戒经验探讨收集患者报告的意义[J]. 中国药物警戒, 2023, 20(9): 978-981.
[15]	刘文东, 崔欢欢, 王晓晗, 苏娴, 王海学. 我国儿童用药临床试验期间药物警戒监管体系现状及思考[J]. 中国药物警戒, 2023, 20(9): 1002-1006.